Literature DB >> 3729366

Anticandidal activities of terconazole, a broad-spectrum antimycotic.

E L Tolman, D M Isaacson, M E Rosenthale, J L McGuire, J Van Cutsem, M Borgers, H Van den Bossche.   

Abstract

Terconazole is a new triazole ketal derivative with broad-spectrum in vitro and in vivo antifungal activities. This study further characterizes the effects of terconazole in vitro on yeast cell growth, viability, and morphology. Terconazole inhibited the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 10(-8) to 10(-5) M when the yeast was grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varied with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole was markedly enhanced when the yeast was grown on Eagle minimum essential medium, which favors mycelium formation. The effects of terconazole on the morphology of yeast cells (grown on Eagle minimum essential medium) were shown by phase-contrast and electron microscopy. There is a progression of changes, from loss of mycelia formation at 10(-8) M terconazole through complete necrosis at 10(-4) M.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729366      PMCID: PMC180489          DOI: 10.1128/AAC.29.6.986

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Inhibition of ergosterol synthesis in Candida albicans by ketoconazole [proceedings].

Authors:  H Van Den Bossche; G Willemsens; W Cools; F Cornelissen
Journal:  Arch Int Physiol Biochim       Date:  1979-10

2.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans.

Authors:  H van den Bossche; G Willemsens; W Cools; W F Lauwers; L Le Jeune
Journal:  Chem Biol Interact       Date:  1978-04       Impact factor: 5.192

3.  Biochemical effects of miconazole on fungi. I. Effects on the uptake and or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans.

Authors:  H Van den Bossche
Journal:  Biochem Pharmacol       Date:  1974-02-15       Impact factor: 5.858

4.  The action of miconazole of the growth of Candida albicans.

Authors:  H Van Den Bossche; G Willemsens; J M Van Cutsem
Journal:  Sabouraudia       Date:  1975-03

5.  The activity of ketoconazole in mixed cultures of fungi and human fibroblasts.

Authors:  F Aerts; M De Brabander; H van den Bossche; J van Cutsem; M Borgers
Journal:  Mykosen       Date:  1980-02

6.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

7.  The interaction of miconazole and ketoconazole with lipids.

Authors:  H Van den Bossche; J M Ruysschaert; F Defrise-Quertain; G Willemsens; F Cornelissen; P Marichal; W Cools; J Van Cutsem
Journal:  Biochem Pharmacol       Date:  1982-08-15       Impact factor: 5.858

8.  Terconazole - a new broad-spectrum antifungal.

Authors:  J Van Cutsem; F Van Gerven; R Zaman; P A Janssen
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

9.  Promotion of pseudomycelium formation of Candida albicans in culture: a morphological study of the effects of miconazole and ketoconazole.

Authors:  M Borgers; M De Brabander; H Van Den Bossche; J Van Cutsem
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

10.  The preservation of subcellular organelles of Candida albicans with conventional fixatives.

Authors:  M Borgers; S De Nollin
Journal:  J Cell Biol       Date:  1974-08       Impact factor: 10.539

  10 in total
  8 in total

Review 1.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Fabrication of Highly Deformable Bilosomes for Enhancing the Topical Delivery of Terconazole: In Vitro Characterization, Microbiological Evaluation, and In Vivo Skin Deposition Study.

Authors:  Shaimaa Mosallam; Nermin M Sheta; Ahmed Hassen Elshafeey; Aly Ahmed Abdelbary
Journal:  AAPS PharmSciTech       Date:  2021-02-14       Impact factor: 3.246

4.  Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis.

Authors:  G E Stein; N Mummaw
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Use of Novasomes as a Vesicular Carrier for Improving the Topical Delivery of Terconazole: In Vitro Characterization, In Vivo Assessment and Exploratory Clinical Experimentation.

Authors:  Shaimaa Mosallam; Maha H Ragaie; Noha H Moftah; Ahmed Hassen Elshafeey; Aly Ahmed Abdelbary
Journal:  Int J Nanomedicine       Date:  2021-01-08

Review 6.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

Review 7.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

8.  Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability.

Authors:  Nada Zaghloul; Nada M El Hoffy; Azza A Mahmoud; Nermeen A Elkasabgy
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.